Free Trial

Danaher (DHR) Competitors

Danaher logo
$200.70 +1.07 (+0.54%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$200.25 -0.45 (-0.22%)
As of 07:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DHR vs. RGEN, A, CR, CSL, GFF, IQV, MTD, TMO, MMM, and ELV

Should you be buying Danaher stock or one of its competitors? The main competitors of Danaher include Repligen (RGEN), Agilent Technologies (A), Crane (CR), Carlisle Companies (CSL), Griffon (GFF), IQVIA (IQV), Mettler-Toledo International (MTD), Thermo Fisher Scientific (TMO), 3M (MMM), and Elevance Health (ELV).

Danaher vs. Its Competitors

Danaher (NYSE:DHR) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Danaher has a net margin of 15.81% compared to Repligen's net margin of -3.93%. Danaher's return on equity of 10.80% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Danaher15.81% 10.80% 6.89%
Repligen -3.93%4.53%3.17%

Danaher has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

79.1% of Danaher shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 11.2% of Danaher shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Danaher presently has a consensus target price of $248.00, suggesting a potential upside of 23.57%. Repligen has a consensus target price of $170.75, suggesting a potential upside of 32.82%. Given Repligen's higher probable upside, analysts plainly believe Repligen is more favorable than Danaher.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Danaher
0 Sell rating(s)
4 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.80
Repligen
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69

Danaher has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Danaher$23.88B6.02$3.90B$5.1538.97
Repligen$634.44M11.38-$25.51M-$0.45-285.69

In the previous week, Danaher had 46 more articles in the media than Repligen. MarketBeat recorded 56 mentions for Danaher and 10 mentions for Repligen. Danaher's average media sentiment score of 1.54 beat Repligen's score of 0.82 indicating that Danaher is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Danaher
51 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Repligen
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Danaher beats Repligen on 12 of the 16 factors compared between the two stocks.

Get Danaher News Delivered to You Automatically

Sign up to receive the latest news and ratings for DHR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DHR vs. The Competition

MetricDanaherMedical Services IndustryMedical SectorNYSE Exchange
Market Cap$142.87B$7.24B$5.47B$20.52B
Dividend Yield0.64%2.83%5.25%3.78%
P/E Ratio38.9727.3326.9927.79
Price / Sales6.0234.17428.7140.41
Price / Cash18.2723.6936.8222.26
Price / Book2.936.727.984.58
Net Income$3.90B$230.16M$3.16B$982.91M
7 Day Performance-0.88%1.12%2.38%0.41%
1 Month Performance0.72%2.31%2.17%3.59%
1 Year Performance-16.31%49.95%33.81%14.47%

Danaher Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DHR
Danaher
4.8894 of 5 stars
$200.70
+0.5%
$248.00
+23.6%
-16.6%$142.87B$23.88B38.9763,000Positive News
Analyst Forecast
RGEN
Repligen
4.7914 of 5 stars
$124.24
+0.6%
$172.83
+39.1%
+7.3%$6.98B$634.44M-276.091,778Analyst Forecast
A
Agilent Technologies
4.7245 of 5 stars
$118.22
-0.8%
$140.92
+19.2%
-3.9%$33.58B$6.51B29.1918,100Positive News
Analyst Forecast
CR
Crane
3.3494 of 5 stars
$188.81
+0.2%
$197.75
+4.7%
+34.5%$10.86B$2.18B25.0111,000Trending News
CSL
Carlisle Companies
4.2182 of 5 stars
$374.53
+0.1%
$461.67
+23.3%
-2.1%$16.20B$5.00B13.945,500
GFF
Griffon
4.9547 of 5 stars
$72.14
-0.7%
$98.20
+36.1%
+22.2%$3.39B$2.62B14.945,300
IQV
IQVIA
4.8948 of 5 stars
$157.50
+0.0%
$226.32
+43.7%
-21.2%$27.25B$15.41B21.4686,000Positive News
MTD
Mettler-Toledo International
4.3319 of 5 stars
$1,172.22
-1.0%
$1,300.36
+10.9%
-9.3%$24.36B$3.87B29.2318,000Positive News
Analyst Forecast
TMO
Thermo Fisher Scientific
4.9916 of 5 stars
$404.86
-0.8%
$604.05
+49.2%
-20.4%$152.83B$42.88B23.75125,000Positive News
Analyst Forecast
MMM
3M
4.2021 of 5 stars
$152.07
+0.0%
$155.83
+2.5%
+52.0%$81.84B$24.58B19.2092,000Positive News
ELV
Elevance Health
4.9548 of 5 stars
$388.91
+1.9%
$498.87
+28.3%
-33.7%$87.87B$183.12B15.17102,300Trending News

Related Companies and Tools


This page (NYSE:DHR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners